Impact of metabolic dysfunction-associated steatotic liver disease on liver metastases and survival in colorectal cancer: a retrospective cohort study
Scandinavian Journal of Gastroenterology, cilt.61, sa.5, ss.525-534, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 61 Sayı: 5
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/00365521.2026.2633728
- Dergi Adı: Scandinavian Journal of Gastroenterology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO)
- Sayfa Sayıları: ss.525-534
- Anahtar Kelimeler: MASLD, colorectal cancer, liver metastasis, survival, hepatosteatosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: This study investigates the impact of the presence and severity of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) on prognosis and metastasis in patients with colorectal cancer (CRC). Methods: This retrospective observational study included 242 CRC patients who underwent PET-CT imaging at a tertiary university hospital in Turkey between 2014 and 2019. Hepatosteatosis presence and severity were assessed via non-contrast CT. Demographic data, BMI, comorbidities, smoking history, family history, cancer stage, metastasis status, laboratory results, and FIB-4 scores were recorded. Relationships between hepatosteatosis and survival, metastases, and lab findings were analyzed. Results: The mean age was 62.4 ± 11.6 years; 64.5% were female. Hepatosteatosis was present in 125 patients (51.7%), with 90 having mild-to-moderate and 35 having severe hepatosteatosis. BMI was significantly lower in patients without hepatosteatosis (p < 0.002). Rates of liver and extrahepatic metastases at diagnosis were significantly higher in patients with hepatosteatosis compared to those without (p < 0.05). Additionally, stage 4C cancer was more common among patients with hepatosteatosis (p < 0.05). Conclusions: This study, the first to explore CRC metastases in MASLD patients, shows a significant association between MASLD and liver metastases. CRC patients with MASLD had higher rates of advanced-stage disease and liver metastases at diagnosis, correlating with shorter survival and poorer prognosis. These findings underscore the importance of early screening and monitoring in CRC patients with MASLD.